Literature DB >> 22130817

The role of the right ventricle in pulmonary arterial hypertension.

A Vonk Noordegraaf1, N Galiè.   

Abstract

Although changes in the pulmonary vasculature are the primary cause of pulmonary arterial hypertension (PAH), severity of symptoms and survival are strongly associated with right ventricular function, and right heart failure is the main cause of death in patients with PAH. Echocardiography and cardiac magnetic resonance imaging allow noninvasive evaluation of right ventricular function and structure, and a number of indices have been shown to have potential prognostic value in PAH. Given the importance of the right ventricle in PAH, preservation and improvement of its function should be important aspects of therapy; however, there are currently few data specifically related to this aspect of treatment response. Simple, reproducible, noninvasive measures of right ventricular function would help to improve the management of patients with PAH, and to provide tools with which to help establish the optimal therapeutic approach to manage not only the effects of the disease on the pulmonary vasculature, but also to support and improve right ventricular function.

Entities:  

Mesh:

Year:  2011        PMID: 22130817     DOI: 10.1183/09059180.00006511

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  79 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 2.  Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Authors:  Marios Panagiotou; Andrew J Peacock; Martin K Johnson
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 3.  The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).

Authors:  Michael R Bristow; Robert A Quaife
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

4.  Pulmonary Hypertension in CKD: Some Answers, Yet More Questions.

Authors:  Mark J Sarnak; Kari E Roberts
Journal:  J Am Soc Nephrol       Date:  2015-09-18       Impact factor: 10.121

5.  Management of Right Ventricular Failure in Pulmonary Hypertension (and After LVAD Implantation).

Authors:  Brittany Palmer; Brent Lampert; Michael A Mathier
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

6.  Left Ventricular Function Before and After Aerobic Exercise Training in Women With Pulmonary Arterial Hypertension.

Authors:  Joshua G Woolstenhulme; Andrew A Guccione; Jeffrey E Herrick; John P Collins; Steven D Nathan; Leighton Chan; Randall E Keyser
Journal:  J Cardiopulm Rehabil Prev       Date:  2019-03       Impact factor: 2.081

Review 7.  The right ventricle under pressure: evaluating the adaptive and maladaptive changes in the right ventricle in pulmonary arterial hypertension using echocardiography (2013 Grover Conference series).

Authors:  Alexis Harrison; Nathan Hatton; John J Ryan
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

8.  The prognostic significance of pulmonary arterial capacitance in pulmonary arterial hypertension: single-center experience.

Authors:  Nadine Al-Naamani; Ioana R Preston; Nicholas S Hill; Kari E Roberts
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

9.  Analysis of the microRNA signature driving adaptive right ventricular hypertrophy in an ovine model of congenital heart disease.

Authors:  Rebecca Johnson Kameny; Youping He; Terry Zhu; Wenhui Gong; Gary W Raff; Cheryl J Chapin; Sanjeev A Datar; Jason T Boehme; Akiko Hata; Jeffrey R Fineman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

Review 10.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.